Form 4 for KRSA Korsana Biosciences, Inc.
Accepted 2024-11-25 00:00:00 ET · period of report 2024-11-21 · accession 0000902664-24-006775 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-11-25 | 2024-11-21 | KRSA | Greenspan David Gerald | 10% | S - Sale | $1.55 | -357.9K | 0 | -100% | -$554.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, no par value | 2024-11-21 | S | D | 357,880 | $1.55 | 0 | I See footnote | — | — | (F1) The number of shares reported herein reflect the one-for-twenty reverse stock split effected by the Issuer on May 15, 2023. (F2) The securities to which this filing relates were held by certain funds (the "Slate Path Funds"). Slate Path Capital LP (the "Investment Manager"), a Delaware limited partnership acts as the investment manager of the Slate Path Funds. Mr. David Greenspan serves as the managing member of Jades GP, LLC, a Delaware limited liability company and the general partner of the Investment Manager. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any. |